{"id":740973,"date":"2023-03-17T07:03:35","date_gmt":"2023-03-17T11:03:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-highlighted-in-forbes-article\/"},"modified":"2023-03-17T07:03:35","modified_gmt":"2023-03-17T11:03:35","slug":"tiziana-life-sciences-highlighted-in-forbes-article","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-highlighted-in-forbes-article\/","title":{"rendered":"Tiziana Life Sciences Highlighted in Forbes Article"},"content":{"rendered":"

\nArticle entitled “New T Cell Antibody Treatment Improves Outcomes For Covid Patients” reviews the company’s first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases
\n<\/h2>\n
\n

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd.\u00a0(Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company was highlighted in a FORBES article highlighting foralumab, the Company’s unique intranasal monoclonal antibody, which is currently in clinical development to treat multiple sclerosis and a range of other neurodegenerative diseases. Foralumab is the world\u2019s only fully human, anti-CD3 mAb in clinical development.<\/p>\n

Forbes contributing author, William A. Haseltine<\/strong><\/a>, highlighted foralumab in his article entitled “New T Cell Antibody Treatment Improves Outcomes for Covid Patients”<\/em>.<\/p>\n

Noted in the article was:
\u201cForalumab induces many factors that impact improved tissue remodeling, induction of immune cells, and restriction of effector function, improving disease outcomes while fighting the virus to full strength. These benefits are not limited to Covid-19 patients, as similar results were observed in patients with multiple sclerosis.\u201d<\/em><\/p>\n

\n \u201cThe anti-CD3 monoclonal treatment effectively modulates the T cell inflammatory response by up or downregulating specific gene and protein expressions, resulting in less severe disease. This novel avenue should be further explored, as more drugs with similar mechanisms could<\/em>
\n prevent the deaths of thousands.\u201d<\/em>\n <\/p>\n

\n To access the full Forbes article, please visit the following hyperlink:<\/strong>\n <\/p>\n